WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, a company spearheading the movement to restore hearing by harnessing the regenerative potential of progenitor cells in the body, today announced that Chris Loose, Ph.D., the Company’s Co-founder and Chief Scientific Officer, will be presenting at the 14th Stem Cell Research and Regenerative Medicine Conference. The presentation titled, “Progenitor Cell Activation - an Enabling Technology for In-Situ Tissue Regeneration,” will look to explore the company’s proprietary Progenitor Cell Activation (PCA™) platform, founded on recent discoveries in progenitor cell biology by Bob Langer, Sc.D. at MIT and Jeff Karp, Ph.D., at Harvard. PCA is leading to a new class of drugs that regenerate healthy tissue within the body. The presentation will take place on Wednesday, April 5 at 4:50 p.m. The conference is being held from April 5 to 6 in Boston, MA.
“The biology, chemistry and regenerative properties behind our PCA platform is quite exciting and has the potential to yield a whole new category of disease-modifying therapeutics for a wide range of degenerative conditions,” said Dr. Loose. “Our lead program is focused on the over 360 million people worldwide who suffer from hearing impairment, with no effective therapeutic solutions currently available. By targeting cellular regeneration within the inner ear to restore healthy tissue and reverse hearing loss, we look to develop a direct therapeutic approach through a locally applied drug without the need for surgical interventions.”
“Chris has provided exceptional leadership in translating the vision of our founders, Bob Langer and Jeff Karp, into a successful product development organization,” said David Lucchino, President, Co-founder and CEO of Frequency. “This presentation exemplifies the core of the research and development Frequency is performing with our PCA platform, and addresses our intent of advancing a first-in-class therapeutic option for chronic hearing loss.”
ABOUT PROGENITOR CELL ACTIVATION (PCA™)
Frequency’s precise
and controlled approach transiently causes Lgr5+ progenitor cells to
divide and differentiate, much like what is seen in naturally
regenerating tissues such as the skin and intestine. Frequency activates
‘stemness’ through mimicking signals provided by neighboring cells (the
stem cell niche) with small molecules, and this proprietary approach is
known as the Progenitor Cell Activation (PCA™) platform. Frequency
believes that PCA has the potential to yield a whole new category of
disease-modifying therapeutics for a wide range of degenerative
conditions. To fuel its drug discovery programs, Frequency is leveraging
a PCA screening platform using primary human cells, including cochlear
progenitor cells and adult human progenitor cells from the GI tract.
Frequency’s initial focus is on chronic noise induced hearing loss.
Other potential applications include skin disorders, gastrointestinal
diseases, and diabetes.
ABOUT FREQUENCY THERAPEUTICS
Frequency Therapeutics develops
small molecule drugs that activate progenitor cells within the body to
restore healthy tissue. Through the transitory activation of these
progenitor cells, Frequency enables disease modification without the
complexity of genetic engineering. Our lead program re-creates sensory
cells in the inner ear to treat chronic noise induced hearing loss,
which affects over 30 million people in the U.S. alone. www.frequencytx.com.
